In a report issued on July 28, Jonathan Chang from SVB Securities reiterated a Hold rating on Athenex (ATNX – Research Report), with a price target of $1.00. The company's shares closed last Friday at $0.51, close to its 52-week low of $0.41. According to TipRanks.com, Chang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -14.0% and a 29.2% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Athenex with a $3.00 average price target.
https://www.tipranks.com/news/blurbs/svb-securities-reiterates-a-hold-rating-on-athenex-atnx?utm_source=advfn.com&utm_medium=referral